Giuliano Elia

Philochem (Switzerland) — Switzerland

Medicine · Health Sciences

46h-index10.4kcitations171works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(27), Monoclonal and Polyclonal Antibodies Research(24), Immunotherapy and Immune Responses(23), Advanced Proteomics Techniques and Applications(16), Cancer Immunotherapy and Biomarkers(15)

Publications171 total

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
Annals of Oncology·2025· 4 citedOpen Access
Intratumoral administration of daromun in non‐melanoma skin cancer: Preliminary results from a phase 2 non‐randomized controlled trial
Journal of the European Academy of Dermatology and Venereology·2024· 4 citedOpen Access
Intralesional administration of L19IL2/L19TNF in high-risk locally advanced basal cell carcinoma or cutaneous squamous cell carcinoma.
Journal of Clinical Oncology·2024
Cooperação agrícola, investimentos e exportações do Brasil na África (2003-2016): a hegemonia do projeto do capitalismo agrário: as relações internacionais entre blocos no poder e as lutas de classes
Dialética eBooks·2024
1138P Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Annals of Oncology·2023· 3 citedOpen Access
Intralesional administration of L19IL2/L19TNF in difficult-to-treat BCC patients shows favorable safety profile and leads to complete remission of tumor lesions
2023
Supplementary Figure 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Table 1 from Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A <sup>124</sup>I-L19SIP Dosimetric PET Study
2023Open Access
Supplementary Figure 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Methods from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Figure 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Table 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Table 1 from Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A <sup>124</sup>I-L19SIP Dosimetric PET Study
2023Open Access
Supplementary Figure 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Methods from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Table 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Table 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Data from Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A <sup>124</sup>I-L19SIP Dosimetric PET Study
2023Open Access
Data from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
Supplementary Table 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Dario Neri(15), Kenneth A. Dawson(5), Antonio Rossi(5), Iseult Lynch(4), Leonardo Giovannoni(4), M.G. Santoro(4), Nicholas A. Wright(3), Jascha‐N. Rybak(3), Stephan Scheurer(3), Richard Poulsom(3), Alessio Di Luca(3), Anne Maria Mullen(3), Ruth M. Hamill(3), Kieran Wynne(3), Massimo Santoro(3), Christoph Roesli(3), Martin Lundqvist(2), Johannes Stigler(2), Tommy Cedervall(2), Marco P. Monopoli(2)